Twist Bioscience Insiders Sell $25M Into AI-Driven Rally
Twist Bioscience shares trade roughly 29% above analyst consensus on a reported guidance hike and Anthropic-linked AI announcement, yet insiders net-sold $24.97M with zero purchases during the rally.
Twist Bioscience Insiders Sell $25M Into AI-Driven Rally
NEW YORK, August 20 —
Twist Bioscience Corporation (TWST) shares trade roughly 29% above analyst consensus following a reported guidance hike and Anthropic-linked AI announcement, yet insiders net-sold $24.97M with zero purchases during the same rally. The company's most recent quarter recorded a 211.1% earnings miss and negative free cash flow.
- Revenue grew 23.2% year-over-year to $430M trailing twelve months; gross margin stands at 52.0%.
- Operating cash flow was -$53M and free cash flow was -$65M on a trailing basis.
- Twist completed a $300M capital raise in August 2026, with prospectus supplements filed August 4 and 5.
The Selling Pattern
Twist's insider transaction record ran opposite to the rally that lifted shares to $136.33. Executives and directors net-sold $24.97M with zero purchases during the period the stock climbed. The company manufactures synthetic DNA-based products including synthetic genes, oligo pools, and antibody optimization libraries serving pharmaceutical and biotech companies in drug discovery, diagnostics, and CRISPR applications. Its NGS portfolio covers library preparation kits, human exome kits, and custom panels for population genetics and translational research, the segments where AI-drug-discovery narratives have the most traction with investors.
From Beats to Misses
The EPS record complicates the guidance narrative. Twist beat consensus estimates by 10.0% four quarters ago and 3.8% three quarters ago, then missed by 13.2% two quarters ago and by 211.1% in the most recent quarter per the August 3 8-K. The $300M capital raise landed within days of those results, confirmed by prospectus supplements dated August 4 and August 5. The shelf registration established in June provided the legal mechanism to raise capital on demand, and the August 19 424B7 indicates the program remained open well after the initial raise.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| TWST | $8.5B | n/a | +437.9% |
| PACB | $382M | n/a | +0.8% |
| TXG | $8.3B | 314.1x | +374.7% |
| BEAM | $2.9B | n/a | +81.6% |
| CDNA | $2.4B | 34.7x | +271.8% |
| NTLA | $1.7B | n/a | +31.2% |
The Cash Burn Test
Three signals define the next checkpoint. Whether operating cash flow narrows from -$53M trailing and free cash flow improves from -$65M will show whether the guidance hike reflects genuine operating leverage or continued reliance on external capital. The August 19 Regulation FD disclosure and same-day 424B7 filing indicate the offering window remains open, a consideration for dilution. Short interest stands at 28.7% of float, amplifying moves in either direction. Run the free Twist Bioscience Corporation deep-dive → for current figures as next quarter's results arrive, or model the revenue trajectory with the DCF calculator.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why are Twist Bioscience insiders selling stock?
Insiders net-sold $24.97M with zero purchases during the period shares climbed to $136.33, roughly 29% above analyst consensus. The selling pattern ran opposite to a rally tied to a reported guidance hike and an Anthropic-linked AI announcement. The article does not attribute a stated reason for the transactions.
What caused the TWST stock rally?
Shares rose roughly 29% above analyst consensus following a reported guidance hike and an Anthropic-linked AI announcement. Twist manufactures synthetic DNA products including synthetic genes and antibody optimization libraries serving pharmaceutical and biotech companies in drug discovery and diagnostics, precisely the segments where AI-drug-discovery narratives have the most traction with investors. Short interest at 28.7% of float amplifies moves in either direction.
What is Twist Bioscience's free cash flow?
Twist Bioscience reported operating cash flow of -$53M and free cash flow of -$65M on a trailing twelve-month basis. The company completed a $300M capital raise in August 2026, with prospectus supplements filed August 4 and 5. An August 19 424B7 filing indicates the offering window remained open after the initial raise.
How did Twist Bioscience perform on recent earnings?
Twist beat consensus by 10.0% four quarters ago and 3.8% three quarters ago, then missed by 13.2% two quarters ago and by 211.1% in the most recent quarter. The $300M capital raise landed within days of those results. Revenue grew 23.2% year-over-year to $430M trailing twelve months, with gross margin at 52.0%.
What is Twist Bioscience's short interest?
Short interest stands at 28.7% of float, which amplifies moves in either direction. An August 19 Regulation FD disclosure and same-day 424B7 filing indicate the offering window remained open, a consideration for dilution. Shares trade at $136.33, roughly 29% above analyst consensus.
Twist Bioscience stock surged on a guidance raise and an Anthropic-linked announcement, yet the CEO and other insiders net-sold $24.97M in shares with zero purchases during the same rally — even as the stock now trades roughly 29% above the analyst consensus price target and short interest sits at 28.7% of float.